Search

Search Constraints

You searched for: Author/Creator Verhoef, Gregor

Search Results

2. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study*. Issue 1 (2nd January 2019)

3. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Issue 1 (2nd January 2019)

5. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Issue 10 (October 2013)

6. Detection of bone marrow involvement in newly diagnosed post-transplant lymphoproliferative disorder: 18F-fluorodeoxyglucose positron emission tomography/computed tomography versus bone marrow biopsy. Issue 10 (2nd October 2016)

7. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Issue 11 (November 2018)

9. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Issue 11 (November 2018)

10. Improving lymph node characterization in staging malignant lymphoma using first‐order ADC texture analysis from whole‐body diffusion‐weighted MRI. Issue 4 (14th April 2018)